The Long COVID Migraine Wave: Why So Many People Started Getting Attacks in 2020

The Wave Nobody Named

Something strange showed up in headache clinics in the spring of 2020. Patients with decades of stable migraine were reporting attacks twice as often. People who had never had a headache in their lives were calling for appointments, describing throbbing, photophobic pain that looked exactly like migraine. Affected regions saw a five-fold jump in headache incidence.^[1] Clinicians blamed lockdown stress at first. Disrupted sleep. Screen time. But the pattern kept going long after lockdowns ended. Something biological was happening — and we finally know what.

Three mechanisms explain it. Inflammation in the trigeminovascular system. Damage to the vagus nerve. Microscopic clots blocking brain capillaries. The data behind each is now substantial.

The Scale of the Wave

Start with the numbers. Headache hits roughly one in four people who get COVID. A meta-analysis pooling 104,751 confirmed cases across 78 studies put cumulative prevalence at 25.2% — roughly twice what other respiratory viruses produce.^[2]

The headaches don’t always go away. A Spanish prospective cohort followed 905 patients for 9 months; 16% still had it, most with a migraine-like phenotype.^[3] A 24-month Brazilian follow-up of 732 patients found de novo headaches lasting up to two years.^[4]

Patients with pre-existing migraine fared worse. In a Kuwaiti study of 121 confirmed cases, average headache days climbed from 8.66 to 11.09 per month after infection — significant at P < .006.^[5] An Italian questionnaire of 102 confirmed cases found 52.94% reporting worsening, every single one with increased attack frequency.^[6] A New York case series of seven patients: six needed to change their preventive regimen. Botox and anti-CGRP antibodies — the standard heavy artillery — worked less well than before.^[7]

The global picture is sobering. By the end of 2021, the Institute for Health Metrics and Evaluation estimated 144.7 million people had developed long COVID, 22 million of them still symptomatic at 12 months.^[8] A 2025 meta-analysis of 429 studies put pooled global prevalence at 36%.^[8] Headache is one of the most common neurological features of it.

Mechanism #1: Neuroinflammation of the Trigeminovascular System

Migraine is, at its core, neurogenic inflammation in the trigeminovascular system — the trigeminal nerve and the blood vessels around the brain. SARS-CoV-2 attacks exactly this circuit.

Entry is through the nose. The virus crosses the olfactory mucosa and rides the trigeminal pathway into the brain — which is why losing your sense of smell is so distinctive.^[9] Once inside, it infects microglia, the brain’s resident immune cells, and switches them into pro-inflammatory mode. They start pumping out interleukin-1β, interleukin-6, and tumor necrosis factor-alpha.^[10] Post-mortem brains from COVID patients show the result: microgliosis, microglial nodules, immune cells infiltrating the medulla oblongata and brainstem.^[11]

What does this do to the headache circuit? In Turkey, a study of 88 hospitalized patients found that those with headache had significantly elevated serum levels of HMGB1, the NLRP3 inflammasome, IL-6, and ACE2 compared to patients without headache. NLRP3 levels correlated with both headache duration and hospital stay length.^[12] The same NLRP3 inflammasome is implicated in pre-pandemic experimental models of migraine.^[12]

And the brain itself physically changes. A UK Biobank study scanned 785 people before and after infection. Compared to controls, those who had COVID showed greater reductions in grey matter thickness in the orbitofrontal cortex and parahippocampal gyrus, with markers of tissue damage in regions connected to the olfactory cortex — even in mild, non-hospitalized cases.^[14]

Mechanism #2: Vagus Nerve Damage and Dysautonomia

The second mechanism is quieter. The vagus nerve runs from the brainstem to nearly every organ in the body. It controls heart rate, digestion, breathing — and crucially, it runs the anti-inflammatory reflex that keeps neuroinflammation from running wild.

SARS-CoV-2 has the keys to this nerve. The receptors it uses to enter cells — ACE2, neuropilin-1, TMPRSS2 — are all expressed on vagal tissue.^[15] A 2023 histopathology study confirmed what this means in practice: vagal nuclei in the brainstems of COVID patients showed elevated HLA-DR+ monocytes and CD8+ T cells. Active inflammation, in the command center of the autonomic nervous system.^[15]

The clinical consequence is dysautonomia — most commonly POTS, postural orthostatic tachycardia syndrome. Autonomic dysfunction affects an estimated 30–50% of long COVID patients with neurological complications.^[16] POTS and migraine overlap heavily: pre-existing migraine raises the risk of post-COVID POTS, and POTS patients have very high headache rates.^[17]

Mechanism #3: Amyloid Microclots in Brain Capillaries

The third mechanism is the most contested — and the most visually striking. In 2020, Resia Pretorius and Douglas Kell at Stellenbosch University began staining blood samples from COVID patients with fluorescent dyes that bind to amyloid proteins. The whole field of view lit up. They were looking at dense, abnormal fibrin clots — smaller than red blood cells, resistant to the body’s normal clot-dissolving machinery.

The 2021 Cardiovascular Diabetology paper that emerged documented these clots in 80 long COVID patients, alongside elevated antiplasmin — explaining why the clots refuse to break down.^[18] Their 2022 review in Biochemical Journal proposed amyloid fibrin microclots as a central mechanism of PASC pathophysiology.^[19] The spike protein alone, in vitro, can trigger amyloid microclot formation in healthy plasma — no live virus needed.^[20] A 2025 study in the Journal of Medical Virology confirmed elevated microclot counts in long COVID patients and showed they cluster with neutrophil extracellular traps — webs of immune debris that further clog small vessels.^[21]

For migraine, the implication is mechanical. Microclots can block brain capillaries, causing patches of micro-ischemia. The picture is biologically similar to what happens during cortical spreading depression — the wave of electrical and metabolic disruption thought to underlie migraine aura.^[22] Add this to an already inflamed trigeminovascular system, and the brain has both the structural and chemical setup for repeated attacks.

The microclot hypothesis is well-replicated but still debated; clinical implications need larger trials before firm conclusions.^[23] Best understood as one of three converging mechanisms — not a single cause.

What Treatments Are Showing

The first wave of clinical data is mixed — and hopeful. Standard migraine treatments often work less well after COVID; many patients in the New York case series needed to switch regimens.^[7] But targeted therapies are showing signal. A Korean case series of nine patients with persistent post-COVID headache treated with CGRP monoclonal antibodies saw monthly headache days fall from 25 to 5, and severity scores drop from 8 to 3.^[24] A Turkish case of a 44-year-old woman with severe post-COVID headache showed near-complete cessation within two days of galcanezumab.^[25] Indomethacin, an NSAID with unusual anti-neuroinflammatory effects, gave more than 50% relief to 36 of 37 patients in a Brazilian study.^[26]

The long view from Spain’s 24-month follow-up is cautiously good: most patients improve over one to two years. The post-COVID migraine wave is not, for most people, a life sentence.^[4] For those still in the middle of it, the science finally points to specific interventions — anti-inflammatory protocols, CGRP-targeted prevention, vagal tone restoration through pacing and gradual reconditioning. Treatment that matches the biology, not just dulls the pain.